Diagnostic performance and pathologic associations of the UroVysion assay in patients with upper tract lesions and negative urinary cytology: a large-scale real-world study of 1,256 patients - Scorecard - MDSpire
Clinical Scorecard: UroVysion Test Accuracy and Pathologic Correlates in 1,256 Patients With Upper Tract Lesions and Negative Urine Cytology: A Real-World Study
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: UroVysion Test Accuracy and Pathologic Correlates in 1,256 Patients With Upper Tract Lesions and Negative Urine Cytology
Key Mechanisms
UroVysion is a fluorescence in situ hybridization assay that identifies aneuploidy involving chromosomes 3, 7, and 17, together with homozygous deletion of 9p21, in exfoliated urothelial cells.
Target Population
Population described in the source article.
Care Setting
Care setting described in the source article.
Key Highlights
The retrospective cohort included 1,256 patients; UTUC was confirmed in 1,007 and 249 were classified as non-cancer.
All patients had imaging-detected upper tract lesions, three consecutive negative urine cytology results under the reporting system in use at the time, and preoperative UroVysion testing.
UroVysion positivity required gains involving at least two probes in at least 4 of 25 morphologically abnormal cells, or homozygous 9p21 deletion in at least 12 cells.
The study aimed to assess diagnostic performance and examine associations between UroVysion positivity and adverse UTUC pathological features.
The supplied excerpt does not report diagnostic performance estimates or results of the pathological association analyses.
Guideline-Based Recommendations
Diagnosis
Study inclusion required three consecutive urine cytology examinations reported as negative under the reporting system in use at the time.
UroVysion testing followed manufacturer instructions; evaluable specimens below the stated positivity thresholds were considered negative.
The reference diagnosis used surgical pathology or biopsy findings with follow-up criteria for patients with negative biopsy findings.
Management
The introduction describes radical nephroureterectomy as standard treatment for UTUC and kidney-sparing surgery as a viable approach for patients with low-risk UTUC.
The study rationale identifies preoperative evaluation as relevant to individualized treatment selection; it does not provide a UroVysion-based treatment recommendation.
Monitoring & Follow-up
Patients with negative biopsy findings were classified in the non-cancer group if imaging showed no disease progression during at least six months of follow-up.
Risks
The introduction notes that ureteroscopic biopsy may involve sampling error, under-staging, under-grading, and intravesical recurrence.
The introduction states that CT urography has limited accuracy for pathological staging and that urinary cytology sensitivity reaches 40–60%.
Patient & Prescribing Data
Retrospective cohort of 1,256 patients with imaging-detected upper tract lesions and negative urinary cytology; 1,007 had confirmed UTUC and 249 were classified as non-cancer.
The excerpt provides no UroVysion-specific treatment outcomes or prescribing data. It describes radical nephroureterectomy as standard UTUC treatment and kidney-sparing surgery as a viable option for low-risk disease.
Clinical Best Practices
In this study, UroVysion results were interpreted using the assay thresholds specified in the methods and manufacturer instructions.
The study repeated urine collection and UroVysion analysis when testing failed or results were suspicious.
UroVysion interpreters were blinded to clinical and pathological information in this study.
The study used final surgical pathology for pathological characteristics, including stage, grade, and lymphovascular invasion.
